Trevena Inc TRVN:NASDAQ

Last Price$0.20NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22

Today's Change-0.007(3.43%)
Bid (Size)$0.21 (40)
Ask (Size)$0.23 (64)
Day Low / High$0.20 - 0.23
Volume1.7 M
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 05/13/2022

 

Trevena Inc ( NASDAQ )

Price: $0.20
Change: -0.007 (3.43%)
Volume: 1.7 M
4:00PM ET 5/13/2022
 
 

TRACON Pharmaceuticals Inc ( NASDAQ )

Price: $1.67
Change: +0.03 (1.83%)
Volume: 83.0 K
3:59PM ET 5/13/2022
 
 

Cumberland Pharmaceuticals Inc ( NASDAQ )

Price: $2.23
Change: 0.00 (0.00%)
Volume: 16.3 K
4:00PM ET 5/13/2022
 
 

ARCA Biopharma Inc ( NASDAQ )

Price: $2.31
Change: +0.02 (0.65%)
Volume: 108.2 K
3:59PM ET 5/13/2022
 
 

Oncternal Therapeutics Inc ( NASDAQ )

Price: $0.70
Change: -0.03 (4.36%)
Volume: 793.9 K
4:00PM ET 5/13/2022
 

Read more news Recent News

--HC Wainwright Lowers Trevena's Price Target to $3.50 From $5, Maintains Buy Rating
1:08PM ET 5/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (TRVN) TREVENA Posts Q1 Revenue $20,000, vs. Street Est of $0.352M
7:00AM ET 5/11/2022 MT Newswires

...

Trevena Says Study on Pain Management Drug Olinvyk Shows Reduced Impact on Respiratory Function on Elderly
8:29AM ET 4/20/2022 MT Newswires

Trevena (TRVN) said Wednesday that a study on Olinvyk, which is intended for the management of acute pain, showed a statistically significant reduced...

Trevena Secures First $15 Million Tranche from Royalty-Based Financing with R-Bridge Healthcare Fund
7:11AM ET 4/18/2022 MT Newswires

Trevena (TRVN) said Monday that it has secured the first $15 million tranche from its royalty-based financing agreement with an affiliate of R-Bridge...

Company Profile

Business DescriptionTrevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA. View company web site for more details
Address955 Chesterbrook Boulevard
Chesterbrook, Pennsylvania 19087
Phone+1.610.354.8840
Number of Employees29
Recent SEC Filing05/11/20228-K
President, Chief Executive Officer & DirectorCarrie L. Bourdow
Chief Financial Officer & Senior Vice PresidentBarry Shin
Chief Medical Officer & Senior Vice PresidentMark A. Demitrack
Vice President-Technical OperationsAngela Bagley

Company Highlights

Price Open$0.23
Previous Close$0.21
52 Week Range$0.18 - 2.20
Market Capitalization$33.6 M
Shares Outstanding165.5 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.32
Beta vs. S&P 500N/A
Revenue$5.7 M
Net Profit Margin-9,098.41%
Return on Equity-62.36%

Analyst Ratings as of 11/26/2021

Buy
3
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset